Expression and Clinicopathological Significance of Foxp3 and VISTA in Cervical Cancer

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2021 Oct 15

PMID 34650712

Citations 9

Authors

Li Li

Xiao-Ting Xu

Li-Li Wang

Song-Bing Qin

Ju-Ying Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: To detect the expression differences of Foxp3 and VISTA in chronic cervical inflammation, cervical intraepithelial neoplasia, and cervical cancer, and to explore the role of Foxp3 and VISTA in the development of cervical cancer and the effect of Foxp3 and VISTA on the prognosis of cervical cancer, to provide a theoretical basis for clinical immunotherapy of cervical cancer.

Methods: We collected 130 paraffin specimens of cervical tissue, which included 70 cases of cervical cancer tissue, 40 cases of cervical intraepithelial neoplasia tissues and 20 cases of chronic cervicitis. The expression of Foxp3 and VISTA in each group was detected, and the study was conducted based on the clinicopathological characteristics of the patients. The patients were followed up and the prognosis was statistically analyzed.

Result: 1. The expression of Foxp3 and VISTA was statistically different between the cervical cancer group and other groups. 2. Expressions of Foxp3 and VISTA were significantly correlated. 3. In 70 cases of cervical cancer, the expression of Foxp3 and VISTA was related to the clinical stage. 4. The 3-year survival rate of 70 patients with cervical cancer was 72.9%, and there were no factors affecting 3-year OS found. The expression of Foxp3 and VISTA was significantly correlated with the prognosis of cervical cancer. Foxp3 and VISTA double positive expression group had the worst prognosis.

Conclusion: 1. In cervical cancer, the expression of Foxp3 and VISTA was significantly higher than that of cervical intraepithelial neoplasia and chronic cervicitis, which suggested that they were closely related to the occurrence and growth of cervical cancer. 2. The expression of Foxp3 and VISTA was significantly related. 3. The positive expression of Foxp3 and VISTA could be used as independent prognostic factors for cervical cancer prognosis providing a strong basis for cervical cancer immunotherapy.

Citing Articles

The prognostic value of Th17/Treg cell in cervical cancer: a systematic review and meta-analysis.

Zhang J, Zhan J, Guan Z, Lin X, Li T, Li M Front Oncol. 2024; 14:1442103.

PMID: 39324000 PMC: 11422014. DOI: 10.3389/fonc.2024.1442103.

Advances in Foxp3+ regulatory T cells (Foxp3+ Treg) and key factors in digestive malignancies.

Wang W, Ding M, Wang Q, Song Y, Huo K, Chen X Front Immunol. 2024; 15:1404974.

PMID: 38919615 PMC: 11196412. DOI: 10.3389/fimmu.2024.1404974.

The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.

Olbromski M, Mrozowska M, Piotrowska A, Smolarz B, Romanowicz H Cancer Immunol Immunother. 2024; 73(8):136.

PMID: 38833004 PMC: 11150347. DOI: 10.1007/s00262-024-03701-w.

Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.

Rezagholizadeh F, Tajik F, Talebi M, Taha S, Shariat Zadeh M, Farhangnia P Front Immunol. 2024; 15:1283364.

PMID: 38357542 PMC: 10865497. DOI: 10.3389/fimmu.2024.1283364.

VISTA as a prospective immune checkpoint in gynecological malignant tumors: A review of the literature.

Ren R, Chang X, Chen C, Yu H, Han L Open Med (Wars). 2023; 18(1):20230866.

PMID: 38152334 PMC: 10751886. DOI: 10.1515/med-2023-0866.

References

Frenel J, Le Tourneau C, ONeil B, Ott P, Piha-Paul S, Gomez-Roca C . Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017; 35(36):4035-4041. DOI: 10.1200/JCO.2017.74.5471. View

Jang E, Nguyen Q, Kim S, Kim D, Nga Le T, Keslar K . Lung-Infiltrating Foxp3 Regulatory T Cells Are Quantitatively and Qualitatively Different during Eosinophilic and Neutrophilic Allergic Airway Inflammation but Essential To Control the Inflammation. J Immunol. 2017; 199(12):3943-3951. PMC: 5716870. DOI: 10.4049/jimmunol.1700211. View

Brunkow M, Jeffery E, Hjerrild K, Paeper B, Clark L, Yasayko S . Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001; 27(1):68-73. DOI: 10.1038/83784. View

Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F . Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2010; 125(1):65-72. DOI: 10.1007/s10549-010-0831-1. View

Shou J, Zhang Z, Lai Y, Chen Z, Huang J . Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis. BMC Cancer. 2016; 16:687. PMC: 5002190. DOI: 10.1186/s12885-016-2732-0. View

Orbegoso C, Murali K, Banerjee S . The current status of immunotherapy for cervical cancer. Rep Pract Oncol Radiother. 2018; 23(6):580-588. PMC: 6277269. DOI: 10.1016/j.rpor.2018.05.001. View

Ma Q, Hou M, Yang X . Screening of the genital human papillomavirus infection among 8581 women in the First Affiliated Hospital of Xi'an Jiaotong University. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2014; 36(3):277-82. DOI: 10.3881/j.issn.1000-503X.2014.03.009. View

Kim M, Grimmig T, Grimm M, Lazariotou M, Meier E, Rosenwald A . Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One. 2013; 8(1):e53630. PMC: 3559740. DOI: 10.1371/journal.pone.0053630. View

Boger C, Behrens H, Kruger S, Rocken C . The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?. Oncoimmunology. 2017; 6(4):e1293215. PMC: 5414883. DOI: 10.1080/2162402X.2017.1293215. View

10.

Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L . Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11):1015-1026. PMC: 5635424. DOI: 10.1056/NEJMoa1613683. View

11.

Le Mercier I, Chen W, Lines J, Day M, Li J, Sergent P . VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res. 2014; 74(7):1933-44. PMC: 4116689. DOI: 10.1158/0008-5472.CAN-13-1506. View

12.

Winerdal M, Marits P, Winerdal M, Hasan M, Rosenblatt R, Tolf A . FOXP3 and survival in urinary bladder cancer. BJU Int. 2011; 108(10):1672-8. DOI: 10.1111/j.1464-410X.2010.10020.x. View

13.

Zhao H, Zhang X, Han Z, Xie W, Yang W, Wei J . Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer. Sci Rep. 2018; 8(1):9847. PMC: 6026197. DOI: 10.1038/s41598-018-28277-1. View

14.

Fuereder T . Immunotherapy for head and neck squamous cell carcinoma. Memo. 2016; 9:66-69. PMC: 4923082. DOI: 10.1007/s12254-016-0270-8. View

15.

Balermpas P, Martin D, Wieland U, Rave-Frank M, Strebhardt K, Rodel C . Human papilloma virus load and PD-1/PD-L1, CD8 and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. Oncoimmunology. 2017; 6(3):e1288331. PMC: 5384387. DOI: 10.1080/2162402X.2017.1288331. View

16.

Li Z, Song W, Rubinstein M, Liu D . Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol. 2018; 11(1):142. PMC: 6303854. DOI: 10.1186/s13045-018-0684-3. View

17.

Peters S, Kerr K, Stahel R . PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treat Rev. 2017; 62:39-49. DOI: 10.1016/j.ctrv.2017.10.002. View

18.

Peng J, Yu Z, Xue L, Wang J, Li J, Liu D . The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells. Mol Med Rep. 2018; 17(4):5860-5868. PMC: 5866031. DOI: 10.3892/mmr.2018.8606. View

19.

Kim J, Kim B, Lee S . Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy. Immune Netw. 2020; 20(1):e4. PMC: 7049587. DOI: 10.4110/in.2020.20.e4. View

20.

Franzen A, Vogt T, Muller T, Dietrich J, Schrock A, Golletz C . () and () promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas. Oncotarget. 2018; 9(1):641-650. PMC: 5787495. DOI: 10.18632/oncotarget.23080. View